JP4975324B2
(ja)
*
|
2002-11-09 |
2012-07-11 |
イムノコア リミテッド |
T細胞レセプターディスプレイ
|
ZA200604620B
(en)
|
2003-12-10 |
2007-10-31 |
Medarex Inc |
IP-10 antibodies and their uses
|
EP2418220B1
(en)
|
2003-12-10 |
2017-08-02 |
E. R. Squibb & Sons, L.L.C. |
Interferon alpha antibodies and their uses
|
CN102863532A
(zh)
|
2004-06-21 |
2013-01-09 |
米德列斯公司 |
干扰素α受体1抗体及其用途
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
EP1899379B1
(en)
|
2005-06-20 |
2018-04-11 |
E. R. Squibb & Sons, L.L.C. |
Cd19 antibodies and their uses
|
SG163554A1
(en)
|
2005-07-01 |
2010-08-30 |
Medarex Inc |
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
|
MY144906A
(en)
|
2005-10-21 |
2011-11-30 |
Novartis Ag |
Human antibodies against il13 and therapeutic uses
|
JP5512128B2
(ja)
|
2005-12-08 |
2014-06-04 |
メダレックス・リミテッド・ライアビリティ・カンパニー |
フコシルgm1に対するヒトモノクローナル抗体および抗フコシルgm1を使用するための方法
|
US8278421B2
(en)
|
2006-03-20 |
2012-10-02 |
Xoma Techolology Ltd. |
Human antibodies specific for gastrin materials and methods
|
BRPI0715332A2
(pt)
|
2006-08-04 |
2013-10-08 |
Novartis Ag |
Anticorpo, métodos de triar um anticorpo quanto ao domínio extracelular de uma proteína ephb3 útil para o tratamento de câncer, de alterar sistemicamente os anticorpos e triar um anticorpo quanto ao domínio extracelular de uma proteína ephb3 para o tratamento de câncer, de tratar um paciente que sofre de câncer, de alvejar uma célula tumoral que expressa epbh3, e de usar a célula hospedeira, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, composição farmacêutica, e kit.
|
TW200817437A
(en)
|
2006-08-11 |
2008-04-16 |
Medarex Inc |
Monoclonal antibodies against stromal cell derived factor-1 (SDF-1)
|
EP2423231A3
(en)
|
2006-08-18 |
2012-05-30 |
Novartis AG |
PRLR-specific antibody and uses thereof
|
JP2010502220A
(ja)
|
2006-09-05 |
2010-01-28 |
メダレックス インコーポレーティッド |
骨形態形成タンパク質およびその受容体に対する抗体ならびにその使用方法
|
CN103897058B
(zh)
|
2006-10-02 |
2018-06-15 |
E.R.施贵宝&圣斯有限责任公司 |
结合cxcr4的人类抗体及其用途
|
DK2068922T3
(da)
|
2006-10-19 |
2012-10-08 |
Csl Ltd |
Anti-IL-13Ralfa1-antistoffer samt deres anvendelser
|
US8618248B2
(en)
|
2006-10-31 |
2013-12-31 |
President And Fellows Of Harvard College |
Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
|
TW200837081A
(en)
|
2006-11-15 |
2008-09-16 |
Medarex Inc |
Human monoclonal antibodies to BTLA and methods of use
|
KR101552735B1
(ko)
|
2006-12-01 |
2015-09-14 |
메다렉스, 엘.엘.시. |
씨디22에 결합하는 인간 항체 및 이의 용도
|
EP2494988B1
(en)
|
2006-12-07 |
2015-09-30 |
Novartis AG |
Antagonist antibodies against EPHB3
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
WO2008074004A2
(en)
|
2006-12-14 |
2008-06-19 |
Medarex, Inc. |
Human antibodies that bind cd70 and uses thereof
|
TR201904866T4
(tr)
|
2007-09-04 |
2019-04-22 |
Compugen Ltd |
Polipeptidler ve polinükleotidler ve bunların ilaç ve biyolojik madde üretmek için bir ilaç hedefi olarak kullanımları.
|
TWI489993B
(zh)
|
2007-10-12 |
2015-07-01 |
Novartis Ag |
骨硬化素(sclerostin)抗體組合物及使用方法
|
WO2009056634A2
(en)
|
2007-11-02 |
2009-05-07 |
Novartis Ag |
Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
|
AU2008337517B2
(en)
|
2007-12-14 |
2014-06-26 |
Novo Nordisk A/S |
Antibodies against human NKG2D and uses thereof
|
RU2528736C2
(ru)
|
2008-02-05 |
2014-09-20 |
Бристоль-Мейерз Сквибб Компани |
Антитела против альфа5-бета 1 и их применение
|
JP5504587B2
(ja)
*
|
2008-05-27 |
2014-05-28 |
東レ株式会社 |
分析用チップ
|
CA2732782C
(en)
|
2008-08-05 |
2019-02-26 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c5
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
US20110311450A1
(en)
|
2008-12-08 |
2011-12-22 |
Zurit Levine |
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
US8420084B2
(en)
|
2009-03-05 |
2013-04-16 |
Medarex, Inc. |
Fully human antibodies specific to CADM1
|
US9181339B2
(en)
|
2009-04-20 |
2015-11-10 |
Oxford Bio Therapeutics Ltd. |
Antibodies specific to cadherin-17
|
DK2424895T3
(en)
|
2009-04-27 |
2017-12-18 |
Novartis Ag |
Compositions and Methods for Increasing Muscle Growth
|
MX2011011338A
(es)
|
2009-04-27 |
2012-04-19 |
Novartis Ag |
Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12.
|
EP2454376B1
(en)
*
|
2009-07-17 |
2015-12-02 |
Bioatla, LLC |
Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
|
WO2011021146A1
(en)
|
2009-08-20 |
2011-02-24 |
Pfizer Inc. |
Osteopontin antibodies
|
CN102597775A
(zh)
|
2009-09-25 |
2012-07-18 |
佐马技术有限公司 |
筛选方法
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
EP2470569A1
(en)
|
2009-10-13 |
2012-07-04 |
Oxford Biotherapeutics Ltd. |
Antibodies against epha10
|
US9428586B2
(en)
|
2009-12-01 |
2016-08-30 |
Compugen Ltd |
Heparanase splice variant
|
CA2794483C
(en)
|
2010-03-26 |
2020-07-07 |
Trustees Of Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
ES2949159T3
(es)
|
2010-05-06 |
2023-09-26 |
Novartis Ag |
Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6)
|
BR112012028326A2
(pt)
|
2010-05-06 |
2017-03-21 |
Novartis Ag |
anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos
|
US20130189268A1
(en)
|
2010-06-22 |
2013-07-25 |
Precision Biologics, Inc. |
Colon and pancreas cancer specific antigens and antibodies
|
CA2804746C
(en)
*
|
2010-07-16 |
2022-01-11 |
Jay M. Short |
Novel methods of protein evolution
|
US8557248B2
(en)
|
2010-08-09 |
2013-10-15 |
Cyvax, Inc. |
Methods and compositions for treating malaria
|
NZ607337A
(en)
|
2010-08-20 |
2015-06-26 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
US8999335B2
(en)
|
2010-09-17 |
2015-04-07 |
Compugen Ltd. |
Compositions and methods for treatment of drug resistant multiple myeloma
|
CA3182320A1
(en)
|
2010-09-23 |
2012-03-29 |
Precision Biologics, Inc. |
Colon and pancreas cancer peptidomimetics
|
JP2013543384A
(ja)
|
2010-10-05 |
2013-12-05 |
ノバルティス アーゲー |
抗−il12rベータ1抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
|
EP2658971A1
(en)
|
2010-12-28 |
2013-11-06 |
XOMA Technology Ltd. |
Cell surface display using pdz domains
|
CN103596974B
(zh)
|
2011-04-15 |
2016-08-31 |
卡姆普根有限公司 |
多肽和多核苷酸及其用于治疗免疫相关失调和癌症的用途
|
MX351600B
(es)
|
2011-06-03 |
2017-10-20 |
Xoma Technology Ltd |
Anticuerpo especificos para tgf-beta.
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
PT2726508T
(pt)
|
2011-06-28 |
2017-09-26 |
Oxford Biotherapeutics Ltd |
Anticorpos para adp-ribosil ciclase 2
|
CA2836855C
(en)
|
2011-06-30 |
2020-07-14 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
HUE040276T2
(hu)
|
2011-07-01 |
2019-02-28 |
Novartis Ag |
Eljárás metabolikus rendellenességek kezelésére
|
TW201328706A
(zh)
|
2011-12-05 |
2013-07-16 |
Novartis Ag |
表皮生長因子受體3(her3)之抗體
|
KR20140103135A
(ko)
|
2011-12-05 |
2014-08-25 |
노파르티스 아게 |
Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
|
WO2013093762A1
(en)
|
2011-12-21 |
2013-06-27 |
Novartis Ag |
Compositions and methods for antibodies targeting factor p
|
AU2013216320A1
(en)
|
2012-02-01 |
2014-04-03 |
Compugen Ltd. |
C10RF32 antibodies, and uses thereof for treatment of cancer
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
AU2013277051B2
(en)
|
2012-06-22 |
2018-06-07 |
King's College London |
Novel VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
JP6368308B2
(ja)
|
2012-09-07 |
2018-08-01 |
トラスティーズ・オブ・ダートマス・カレッジ |
癌の診断および治療のためのvista調節剤
|
LT2928921T
(lt)
|
2012-12-05 |
2021-04-26 |
Novartis Ag |
Kompozicijos ir būdai, skirti antikūnams nukreipti į epo
|
UY35195A
(es)
|
2012-12-18 |
2014-07-31 |
Novartis Ag |
Composiciones y metodos para proteinas de accion prolongada
|
ES2667333T3
(es)
|
2012-12-28 |
2018-05-10 |
Precision Biologics, Inc. |
Anticuerpos monoclonales humanizados y métodos de uso para el diagnóstico y el tratamiento del cáncer de colon y páncreas
|
MA38322B1
(fr)
|
2013-02-08 |
2018-09-28 |
Novartis Ag |
Anticorps anti-il-17a et leur utilisation dans le traitement de troubles auto-immuns et inflammatoires
|
CN105246916A
(zh)
|
2013-03-14 |
2016-01-13 |
诺华股份有限公司 |
针对notch 3的抗体
|
US9562101B2
(en)
|
2013-06-21 |
2017-02-07 |
Novartis Ag |
Lectin-like oxidized LDL receptor 1 antibodies and methods of use
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
TW201536318A
(zh)
|
2013-08-14 |
2015-10-01 |
Novartis Ag |
治療偶發性包涵體肌炎之方法
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
PL3712174T3
(pl)
|
2013-12-24 |
2022-07-04 |
Janssen Pharmaceutica Nv |
Przeciwciała i fragmenty anty-vista
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
EA037006B1
(ru)
|
2014-06-06 |
2021-01-26 |
Бристол-Майерс Сквибб Компани |
Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения
|
CN107073109B
(zh)
|
2014-06-11 |
2021-08-06 |
凯西·A·格林 |
Vista激动剂和拮抗剂抑制或增强体液免疫的用途
|
WO2015198240A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
US20170291939A1
(en)
|
2014-06-25 |
2017-10-12 |
Novartis Ag |
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
|
US20170290876A1
(en)
|
2014-06-25 |
2017-10-12 |
Novartis Ag |
Compositions and methods for long acting proteins
|
EP3194437B1
(en)
|
2014-08-07 |
2021-01-20 |
Novartis AG |
Angiopoietin-like 4 (angptl4) antibodies and methods of use
|
TN2017000019A1
(en)
|
2014-08-07 |
2018-07-04 |
Novartis Ag |
Angiopoietin-like 4 antibodies and methods of use.
|
DK3221363T3
(da)
|
2014-11-21 |
2020-08-10 |
Bristol Myers Squibb Co |
Antistoffer mod cd73 og anvendelser deraf
|
MX2017007136A
(es)
|
2014-12-05 |
2017-12-04 |
Immunext Inc |
Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8.
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
BR112017025191A2
(pt)
|
2015-05-29 |
2018-07-31 |
Bristol-Myers Squibb Company |
anticorpos contra ox40 e uso dos mesmos
|
CA2982237A1
(en)
|
2015-06-05 |
2016-12-08 |
Novartis Ag |
Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
|
DK3313882T3
(da)
|
2015-06-24 |
2020-05-11 |
Janssen Pharmaceutica Nv |
Anti-VISTA antistoffer og fragmenter
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
EP3331914A1
(en)
|
2015-08-03 |
2018-06-13 |
Novartis AG |
Methods of treating fgf21-associated disorders
|
JP6516925B2
(ja)
|
2015-09-09 |
2019-05-22 |
ノバルティス アーゲー |
胸腺間質性リンパ球新生因子(tslp)結合性抗体および抗体を使用する方法
|
US10000561B2
(en)
|
2015-09-09 |
2018-06-19 |
Novartis Ag |
Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
|
MX2018006072A
(es)
|
2015-11-19 |
2018-08-01 |
Squibb Bristol Myers Co |
Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
|
EP3389711A1
(en)
|
2015-12-18 |
2018-10-24 |
Novartis AG |
Antibodies targeting cd32b and methods of use thereof
|
MX2018009800A
(es)
|
2016-02-12 |
2018-11-09 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
|
EA201891983A8
(ru)
|
2016-03-04 |
2020-05-28 |
Бристол-Майерс Сквибб Компани |
Комбинированная терапия антителами к cd73
|
JP7277047B2
(ja)
|
2016-04-15 |
2023-05-18 |
イミュネクスト インコーポレイテッド |
抗ヒトvista抗体およびその使用
|
JP7138567B2
(ja)
|
2016-04-27 |
2022-09-16 |
ノバルティス アーゲー |
成長分化因子15に対する抗体およびそれらの使用
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
JP7231411B2
(ja)
|
2016-06-15 |
2023-03-01 |
ノバルティス アーゲー |
骨形成タンパク質6(bmp6)の阻害剤を使用して疾患を処置する方法
|
CN109757103B
(zh)
|
2016-07-14 |
2024-01-02 |
百时美施贵宝公司 |
针对tim3的抗体及其用途
|
CA3032146A1
(en)
|
2016-08-03 |
2018-02-08 |
Bio-Techne Corporation |
Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
|
JP7045724B2
(ja)
|
2016-11-07 |
2022-04-01 |
ニューラクル サイエンス カンパニー リミテッド |
配列類似性を持つ抗ファミリー19、メンバーa5抗体及びその用途
|
JP2020500020A
(ja)
|
2016-11-14 |
2020-01-09 |
ノバルティス アーゲー |
融合誘導性タンパク質minionに関連する組成物、方法、および治療上の使用
|
KR102616666B1
(ko)
|
2016-12-23 |
2023-12-27 |
노파르티스 아게 |
인자 xi 항체 및 사용 방법
|
MX2019007924A
(es)
|
2016-12-28 |
2020-01-27 |
Invvax Inc |
Vacunas contra la influenza.
|
FI3580237T3
(fi)
|
2017-02-08 |
2025-07-21 |
Novartis Ag |
FGF21-mimeettivasta-aineita ja niiden käyttöjä
|
CN110461359B
(zh)
|
2017-03-24 |
2025-01-21 |
诺华股份有限公司 |
用于预防和治疗心脏病的方法
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
CN110785433A
(zh)
|
2017-06-28 |
2020-02-11 |
诺华股份有限公司 |
预防和治疗尿失禁的方法
|
EP3700933A1
(en)
|
2017-10-25 |
2020-09-02 |
Novartis AG |
Antibodies targeting cd32b and methods of use thereof
|
AU2018372135A1
(en)
|
2017-11-22 |
2020-05-28 |
Novartis Ag |
Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
|
US12129297B2
(en)
|
2018-01-12 |
2024-10-29 |
Bristol-Myers Squibb Company |
Antibodies against TIM3 and uses thereof
|
US11787857B2
(en)
|
2018-02-02 |
2023-10-17 |
Bio-Techne Corporation |
Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using
|
AU2019236865A1
(en)
|
2018-03-23 |
2020-10-01 |
Bristol-Myers Squibb Company |
Antibodies against MICA and/or MICB and uses thereof
|
TW202513581A
(zh)
|
2018-03-28 |
2025-04-01 |
美商必治妥美雅史谷比公司 |
介白素-2/介白素-2受體阿法融合蛋白及其使用方法
|
CN119569873A
(zh)
|
2018-05-10 |
2025-03-07 |
纽洛可科学有限公司 |
抗序列相似家族19成员a5的抗体及其使用方法
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
JP2022514837A
(ja)
|
2018-12-18 |
2022-02-16 |
ノバルティス アーゲー |
抗第XI/XIa因子抗体に対する反転結合剤及びそれらの使用
|
CN113412281B
(zh)
|
2018-12-26 |
2024-07-23 |
感应检查疗法公司 |
Btn3a结合蛋白及其用途
|
MX2021008796A
(es)
|
2019-01-22 |
2021-11-12 |
Bristol Myers Squibb Co |
Anticuerpos contra subunidad alfa il-7r y usos de estos.
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
WO2021053559A1
(en)
|
2019-09-18 |
2021-03-25 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
EP4182025A1
(en)
|
2020-07-16 |
2023-05-24 |
Novartis AG |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
US12018254B2
(en)
*
|
2020-07-27 |
2024-06-25 |
Wisconsin Alumni Research Foundation |
Methods of making unbiased phage libraries
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型cdcp1に対する抗体およびその使用
|
WO2023217743A1
(en)
|
2022-05-10 |
2023-11-16 |
Imcheck Therapeutics |
Anti-btn3a antibodies for use in methods of treating gastro-intestinal inflammatory disorders
|
WO2025155877A2
(en)
|
2024-01-18 |
2025-07-24 |
The Regents Of The University Of California |
Antibodies binding to pad4 and uses thereof
|